Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
-$4.53 today
- Market cap
- $3.01B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
Volume 2.15M
Average 2.42M
LEGN Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Legend Biotech CorporationNASDAQ: LEGN
Gross Profit · Q3 FY2026 · quarter ended Sep 2026
Gross profit grows, but more slowly than its trailing trend
Q3 FY2026 gross profit of $211.9M rose 34.9% year over year, behind the +40.6% change in trailing-twelve-month gross profit. Sequentially, it fell 15.3% from the prior quarter. Over 3 fiscal years it compounded at +129.1% a year.
Context
- Gross profit amounted to 60.3% of revenue in FY2025, down 2.3 pp from a year earlier.
- Gross profit increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +34.9% toward the trailing-twelve-month pace of +40.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 620.8M USD
- Year-over-year change
- +58.1%
- 4-year CAGR
- +73.3%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 620.8M | +58.1% |
| FY2024 | 2024-12-31 | 392.66M | +178.6% |
| FY2023 | 2023-12-31 | 140.93M | +172.9% |
| FY2022 | 2022-12-31 | 51.64M | -25.0% |
| FY2021 | 2021-12-31 | 68.83M | — |
Gross Profit vs competitors
How LEGN compares with its peers on the latest reported figures
- LEGN's LTM Sep 2026 gross profit of $774.12M is the highest of the 11 companies compared; the peer median is -$6.33M.
- Its year-over-year change of +40.6% is the 5th highest of 11, against a peer median of +4.6%.
- Gross profit amounts to 57.0% of revenue for LEGN, versus a peer median of 96.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $774.12M | +40.6% | +129.1% | 57.0% | |
| LTM Mar 2026 | $55.76M | +43.8% | +80.8% | 81.9% | |
| LTM Mar 2026 | $43.7M | -14.6% | +7.9% | 97.0% | |
| LTM Mar 2026 | $22.24M | -86.1% | — | 96.1% | |
| LTM Mar 2026 | $9.26M | +117.7% | -9.7% | 82.6% | |
| LTM Mar 2026 | -$2.3M | -3640.0% | — | 7422.6% | |
| LTM Mar 2026 | -$10.36M | +93.0% | — | 11.2% | |
| LTM Mar 2026 | -$11.02M | -132.3% | -70.5% | 621.0% | |
| LTM Mar 2026 | -$26.26M | +63.7% | — | 415.8% | |
| LTM Mar 2026 | -$29.86M | -126.0% | +164.4% | — | |
| LTM Mar 2026 | -$77.25M | +23.8% | — | — | |
| Peer median (excluding LEGN) | -$6.33M | +4.6% | +7.9% | 96.5% | |
Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.83M | 117.01M | 285.14M | 627.24M | 1.03B |
| Cost of Revenue | 0 | 65.36M | 144.21M | 234.58M | 408.1M |
| Gross Profit | 68.83M | 51.64M | 140.93M | 392.66M | 620.8M |
| Gross Margin | 100.0% | 44.1% | 49.4% | 62.6% | 60.3% |
| Research & Development | 313.35M | 335.65M | 382.22M | 413.54M | 414.7M |
| Selling, General & Admin | 149.5M | 174.05M | 200.93M | 284.26M | 341.6M |
| Operating Expenses | 461.11M | 507.26M | 580.41M | 695.9M | 757.3M |
| Depreciation & Amortization | 13.92M | 18.39M | 20.45M | 23.36M | 28.9M |
| EBITDA | (392.38M) | (416.54M) | (477.87M) | (113.16M) | (232.3M) |
| EBITDA Margin | -570.1% | -356.0% | -167.6% | -18.0% | -22.6% |
| Operating Income | (392.29M) | (455.62M) | (439.49M) | (303.24M) | (136.5M) |
| Operating Margin | -570.0% | -389.4% | -154.1% | -48.3% | -13.3% |
| Interest Income | 971K | 8.18M | 54.49M | 61.2M | 40.1M |
| Interest Expense | 900K | 10.8M | 21.79M | 21.62M | 21.4M |
| Other Income / Expenses | (14.91M) | 9.9M | (80.63M) | 145.11M | (146.1M) |
| Income Before Tax | (407.2M) | (445.72M) | (520.12M) | (158.13M) | (282.6M) |
| Pre-Tax Margin | -591.6% | -380.9% | -182.4% | -25.2% | -27.5% |
| Income Tax Expense | (3.61M) | 625K | (1.86M) | 18.89M | 14.2M |
| Net Income | (403.58M) | (446.35M) | (518.25M) | (177.03M) | (296.8M) |
| Net Margin | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% |
| EPS (Basic) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| EPS (Diluted) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| Weighted Avg Shares | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
| Weighted Avg Shares (Diluted) | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
Legend Biotech Corporation
NASDAQ:LEGN
Intrinsic Alpha fair value
Locked
Current Price
$16.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.